Onset phase (starting at light onset; 0-2000 s) |
---|
Group | WAKE | SLEEP |
---|
 | Sojourn time (s) | L | U | Sojourn time (s) | L | U |
---|
RD-SSRI
| 212.102 | 155.104 | 290.046 | 25.467 | 16.864 | 38.460 |
HC-SSRI
| 254.713 | 186.264 | 348.315 |
14.176
*
| 9.387 | 21.408 |
RD-VEH
|
374.026
*
| 264.968 | 527.973 | 21.609 | 13.941 | 33.493 |
HC-VEH
| 174.131 | 127.337 | 238.122 | 35.239 | 23.334 | 53.216 |
 |
WAKE→SLEEP
|
SLEEP→WAKE
|
 |
NTR
|
L
|
U
|
NTR
|
L
|
U
|
RD-SSRI
| 0.821 | 0.587 | 1.147 | 1.384 | 0.958 | 1.999 |
HC-SSRI
|
0.684
*
| 0.489 | 0.956 |
2.486
*
| 1.791 | 3.450 |
RD-VEH
|
0.465
*
| 0.323 | 0.670 |
1.631
*
| 1.135 | 2.343 |
- Sojourn time: the estimated mean of the average time span of an event;
- Normalized Transition Rate (NTR): relative transition rate compared to the HC-VEH group (NTR of the HC-VEH group is 1);
- * p < 0.05, significant effect compared to the HC-VEH group;
- L and U: lower and the upper limits of the corresponding 95% confidence interval, respectively;
- Normalized Transition Rate (NTR): relative transition rate compared to the HC-VEH group (NTR of the HC-VEH group is 1);
- Groups: home cage plus chronic vehicle treatment (HC-VEH); home cage plus chronic escitalopram treatment (HC-SSRI); REM sleep deprivation plus chronic vehicle treatment (RD-VEH); REM sleep deprivation plus chronic escitalopram treatment (RD-SSRI).